Peripheral neuropathy in an adolescent treated with linezolid.
The increased incidence of methicillin-resistant Staphyloccocus aureus infections may increase linezolid use in children. Peripheral neuropathy is a rare adverse effect of linezolid therapy and is more frequent with prolonged courses. We present an adolescent with peripheral neuropathy after 4 months of linezolid therapy and review the literature related to linezolid-induced neuropathies. Children receiving long-term linezolid therapy should be monitored for neuropathy.
Linam
W Matthew
WM
Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA. matt.linam@cchmc.org
Wesselkamper
Kristen
K
Gerber
Michael A
MA
D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006801:Humans; D000069349:Linezolid; D010019:Osteomyelitis / Q000188:drug therapy; D023303:Oxazolidinones / Q000009:adverse effects* / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000081:Acetamides; D000588:Amines; D000700:Analgesics; D000900:Anti-Bacterial Agents; D003509:Cyclohexanecarboxylic Acids; D023303:Oxazolidinones; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000069349:Linezolid